Oct 13, 2026 | Alternate Rx sourcing, Biosimilars, Drug costs, High-value formulary, MedBen Rx, Over-the-counter (OTC) drugs, Patient assistance, Specialty Drugs, Spending
Self-funded pharmacy plans rarely have just one cost concern. High-cost brands, combination products, specialty medications, and prescriptions that could be handled over the counter can all drive spending in different ways. Solutions exist, but many PBMs rely on...
Jul 3, 2026 | Acquisition Cost Index (ACI) pricing, Biosimilars, Client Report, Drug costs, Formularies, MedBen Rx, Rx Costs, Specialty Drugs, Spending, Transparency
U.S. pharmaceutical expenditures rose 12.7% in 2025 to $915.2 billion, according to a recent analysis in the American Journal of Health-System Pharmacy. Utilization drove most of the growth, led by high-cost therapies such as tirzepatide, semaglutide, and apixaban....
Apr 20, 2026 | Alternative Reimbursement Strategies, Client Report, Compliance, MedBen Access, MedBen Employees, MedBen News, MedBen University, Pharmacy, Regulatory, Spending, Wellness
MedBen had a full house of employers and brokers in attendance at MedBen University’s (MBU) 25th annual Employer Roundtable on April 16 at the C. Arthur Morrow Conference Center in Newark, Ohio. Presented by MedBen’s team of industry experts, this year’s roundtable...
Dec 30, 2025 | Benefits preservation, Biosimilars, Client Feedback, Client Surveys, Direct-to-Employer Contracting, Forensic claims review, Innovations, Kurt Harden, MedBen Employees, Self-funding, Spending, Third party administration
On behalf of the MedBen team, I wish you a happy and healthy new year, and thank you for your continued trust in MedBen. Our commitment remains to be the benefits partner that employers prefer, and we value the opportunity to serve you. In my 35 years with MedBen,...
Jul 11, 2025 | Cost Savings, Drug advertising, Drug costs, Health care costs, High-value formulary, MedBen Rx, Pharmacy, Rx Costs, Spending
Pharmaceutical advertising hit a record high in 2024, with the top 10 drugs accounting for $3.3 billion in ad spending – up nearly 20% from the previous year. With more campaigns directly targeting consumers, MedBen Rx’s high-value formulary educates members about...
Mar 18, 2024 | DNA, Drug costs, Drugmakers, Gene therapy, Health care costs, Rx Costs, Spending
Back in late 2022, MedBen spotlighted the growth of gene therapy, a transformative medical approach that potentially cures genetic disorders by correcting or replacing an individual’s DNA. As we noted, these therapies go beyond treatment to literally...
